The safety and tolerability of Z-100 in patients infected with HIV-1

Michael Borucki, Mark Holodniy, Gerald Pierone, Peter Ruane, Corklin Steinhart, Sally Williams, Trevor Slom, Frank Palella, C. Bradley Hare, Yasuhisa Yoshida, Xiao Dong Li, Richard B Pollard

Research output: Contribution to journalArticle

Abstract

Z-100 is an extract of the Mycobacterium tuberculosis strain Aoyama B, which contains various polysaccharides. Aoyama B has previously been shown to induce a T helper 1-type cytokine response in various murine oncological models and has also demonstrated inhibitory activity against HIV-1 in vitro. This multicentre study primarily determined the safety of Z-100 in early HIV-1-infected patients who were treatment naive; were treatment experienced, but had elected to discontinue highly active antiretroviral therapy (HAART) 8 weeks or longer before the study; or were stable on their first or second HAART regimen for at least 12 weeks before the study. Thirty-two individuals participated in this study and self-injected either placebo, 20 μg or 40 μg Z-100 twice a week for 8 weeks. Z-100 was well tolerated and the safety profiles of the Z-100 treatment groups were not meaningfully different compared with the placebo group. Plasma levels of HIV-1 RNA were not statistically significantly different in any treatment group at the end of the treatment period. There were no statistically significant differences among the treatment groups in the change from baseline to week 8 for any of the biological endpoints including plasma levels of HIV-1 RNA; CD4+ and CD8+ T-cell counts; levels of macrophage inflammatory protein 1; soluble tumour necrosis factor receptor 1; C-reactive protein; interleukin-6; and granulocyte colony stimulating factor. Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered.

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalAntiviral Therapy
Volume11
Issue number3
StatePublished - 2006

Fingerprint

HIV-1
Safety
Highly Active Antiretroviral Therapy
Therapeutics
Placebos
RNA
Macrophage Inflammatory Proteins
Tumor Necrosis Factor Receptors
Granulocyte Colony-Stimulating Factor
Mycobacterium tuberculosis
C-Reactive Protein
Multicenter Studies
Polysaccharides
specific substance maruyama
Interleukin-6
Cell Count
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Borucki, M., Holodniy, M., Pierone, G., Ruane, P., Steinhart, C., Williams, S., ... Pollard, R. B. (2006). The safety and tolerability of Z-100 in patients infected with HIV-1. Antiviral Therapy, 11(3), 297-303.

The safety and tolerability of Z-100 in patients infected with HIV-1. / Borucki, Michael; Holodniy, Mark; Pierone, Gerald; Ruane, Peter; Steinhart, Corklin; Williams, Sally; Slom, Trevor; Palella, Frank; Hare, C. Bradley; Yoshida, Yasuhisa; Li, Xiao Dong; Pollard, Richard B.

In: Antiviral Therapy, Vol. 11, No. 3, 2006, p. 297-303.

Research output: Contribution to journalArticle

Borucki, M, Holodniy, M, Pierone, G, Ruane, P, Steinhart, C, Williams, S, Slom, T, Palella, F, Hare, CB, Yoshida, Y, Li, XD & Pollard, RB 2006, 'The safety and tolerability of Z-100 in patients infected with HIV-1', Antiviral Therapy, vol. 11, no. 3, pp. 297-303.
Borucki M, Holodniy M, Pierone G, Ruane P, Steinhart C, Williams S et al. The safety and tolerability of Z-100 in patients infected with HIV-1. Antiviral Therapy. 2006;11(3):297-303.
Borucki, Michael ; Holodniy, Mark ; Pierone, Gerald ; Ruane, Peter ; Steinhart, Corklin ; Williams, Sally ; Slom, Trevor ; Palella, Frank ; Hare, C. Bradley ; Yoshida, Yasuhisa ; Li, Xiao Dong ; Pollard, Richard B. / The safety and tolerability of Z-100 in patients infected with HIV-1. In: Antiviral Therapy. 2006 ; Vol. 11, No. 3. pp. 297-303.
@article{da9a752f262c4daa8224fe856fbf7182,
title = "The safety and tolerability of Z-100 in patients infected with HIV-1",
abstract = "Z-100 is an extract of the Mycobacterium tuberculosis strain Aoyama B, which contains various polysaccharides. Aoyama B has previously been shown to induce a T helper 1-type cytokine response in various murine oncological models and has also demonstrated inhibitory activity against HIV-1 in vitro. This multicentre study primarily determined the safety of Z-100 in early HIV-1-infected patients who were treatment naive; were treatment experienced, but had elected to discontinue highly active antiretroviral therapy (HAART) 8 weeks or longer before the study; or were stable on their first or second HAART regimen for at least 12 weeks before the study. Thirty-two individuals participated in this study and self-injected either placebo, 20 μg or 40 μg Z-100 twice a week for 8 weeks. Z-100 was well tolerated and the safety profiles of the Z-100 treatment groups were not meaningfully different compared with the placebo group. Plasma levels of HIV-1 RNA were not statistically significantly different in any treatment group at the end of the treatment period. There were no statistically significant differences among the treatment groups in the change from baseline to week 8 for any of the biological endpoints including plasma levels of HIV-1 RNA; CD4+ and CD8+ T-cell counts; levels of macrophage inflammatory protein 1; soluble tumour necrosis factor receptor 1; C-reactive protein; interleukin-6; and granulocyte colony stimulating factor. Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered.",
author = "Michael Borucki and Mark Holodniy and Gerald Pierone and Peter Ruane and Corklin Steinhart and Sally Williams and Trevor Slom and Frank Palella and Hare, {C. Bradley} and Yasuhisa Yoshida and Li, {Xiao Dong} and Pollard, {Richard B}",
year = "2006",
language = "English (US)",
volume = "11",
pages = "297--303",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "3",

}

TY - JOUR

T1 - The safety and tolerability of Z-100 in patients infected with HIV-1

AU - Borucki, Michael

AU - Holodniy, Mark

AU - Pierone, Gerald

AU - Ruane, Peter

AU - Steinhart, Corklin

AU - Williams, Sally

AU - Slom, Trevor

AU - Palella, Frank

AU - Hare, C. Bradley

AU - Yoshida, Yasuhisa

AU - Li, Xiao Dong

AU - Pollard, Richard B

PY - 2006

Y1 - 2006

N2 - Z-100 is an extract of the Mycobacterium tuberculosis strain Aoyama B, which contains various polysaccharides. Aoyama B has previously been shown to induce a T helper 1-type cytokine response in various murine oncological models and has also demonstrated inhibitory activity against HIV-1 in vitro. This multicentre study primarily determined the safety of Z-100 in early HIV-1-infected patients who were treatment naive; were treatment experienced, but had elected to discontinue highly active antiretroviral therapy (HAART) 8 weeks or longer before the study; or were stable on their first or second HAART regimen for at least 12 weeks before the study. Thirty-two individuals participated in this study and self-injected either placebo, 20 μg or 40 μg Z-100 twice a week for 8 weeks. Z-100 was well tolerated and the safety profiles of the Z-100 treatment groups were not meaningfully different compared with the placebo group. Plasma levels of HIV-1 RNA were not statistically significantly different in any treatment group at the end of the treatment period. There were no statistically significant differences among the treatment groups in the change from baseline to week 8 for any of the biological endpoints including plasma levels of HIV-1 RNA; CD4+ and CD8+ T-cell counts; levels of macrophage inflammatory protein 1; soluble tumour necrosis factor receptor 1; C-reactive protein; interleukin-6; and granulocyte colony stimulating factor. Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered.

AB - Z-100 is an extract of the Mycobacterium tuberculosis strain Aoyama B, which contains various polysaccharides. Aoyama B has previously been shown to induce a T helper 1-type cytokine response in various murine oncological models and has also demonstrated inhibitory activity against HIV-1 in vitro. This multicentre study primarily determined the safety of Z-100 in early HIV-1-infected patients who were treatment naive; were treatment experienced, but had elected to discontinue highly active antiretroviral therapy (HAART) 8 weeks or longer before the study; or were stable on their first or second HAART regimen for at least 12 weeks before the study. Thirty-two individuals participated in this study and self-injected either placebo, 20 μg or 40 μg Z-100 twice a week for 8 weeks. Z-100 was well tolerated and the safety profiles of the Z-100 treatment groups were not meaningfully different compared with the placebo group. Plasma levels of HIV-1 RNA were not statistically significantly different in any treatment group at the end of the treatment period. There were no statistically significant differences among the treatment groups in the change from baseline to week 8 for any of the biological endpoints including plasma levels of HIV-1 RNA; CD4+ and CD8+ T-cell counts; levels of macrophage inflammatory protein 1; soluble tumour necrosis factor receptor 1; C-reactive protein; interleukin-6; and granulocyte colony stimulating factor. Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered.

UR - http://www.scopus.com/inward/record.url?scp=33744741356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744741356&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 297

EP - 303

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 3

ER -